Dr Natalia Gandur speaks to ecancer about the key discussions and consensus themes that emerged from The Advanced Prostate Cancer Consensus Conference (APCCC) 2026.

She explains that the meeting focused on navigating areas of uncertainty in advanced prostate cancer, including treatment intensification, sequencing strategies, molecular testing, PSMA PET imaging, radioligand therapy, and the role of supportive care.

Dr Gandur discusses evolving approaches to metastatic hormone-sensitive and castration-resistant prostate cancer, highlighting the importance of patient selection, biomarker-driven treatment decisions, and the growing integration of genomic testing and PSMA-targeted therapies.

She also explores the challenges of treatment de-escalation, access to advanced diagnostics and therapeutics, frailty assessment, multidisciplinary care, and the need to align treatment choices with individual patient goals and healthcare resources.